Pharmacyclics Inc (PCYC)

Currency in USD
261.25
0.00(0.00%)
Closed·
Showing Pharmacyclics historical data. For real-time data please try another search
Day's Range
260.76261.68
52 wk Range
0.00261.68
Key Statistics
Prev. Close
261.25
Open
260.76
Day's Range
260.76-261.68
52 wk Range
0-0
Volume
-
Average Volume (3m)
1.64M
1-Year Change
0%
Book Value / Share
-
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock

Pharmacyclics Inc Company Profile

Pharmacyclics LLC focuses on developing and commercializing novel therapies for the treatment of cancer and immune-mediated diseases in the United States. The company markets IMBRUVICA, a first-in-class, oral, once-daily, single-agent therapy used for the treatment of patients with: chronic lymphocytic leukemia (CLL) who have received at least one prior therapy; all lines of CLL with deletion of the short arm of chromosome 17; mantle cell lymphoma who have received at least one prior therapy; and all lines of waldenström's macroglobulinemia (WM). Its products candidate in clinical development includes IMBRUVICA BTK inhibitor, which is under phase I, II, III clinical trials for the treatment of CCL, small lymphocytic lymphoma, mantle cell lymphoma, diffuse large B-cell lymphoma, follicular lymphoma, multiple myeloma, WM, marginal zone lymphoma, graft versus host disease, acute lymphoblastic leukemia, acute myeloid leukemia, and solid tumors and others. The company’s product candidates also comprise BTK Inhibitor Program that is in pre-clinical testing, phase I for the treatment of autoimmune; Abexinostat HDAC Inhibitor, which is in phase I and II clinical trials for treating relapsed/refractory lymphomas and solid tumors; and Factor VIIa Inhibitor, which is in phase II complete/program under review for the treatment of cancer. Pharmacyclics LLC has collaboration and license agreement with Janssen Biotech, Inc. to develop and commercialize IMBRUVICA and certain compounds for oncology and other indications. The company was founded in 1991 and is headquartered in Sunnyvale, California. As of May 26, 2015, Pharmacyclics LLC operates as a subsidiary of AbbVie Inc.

Earnings

Latest Release
Feb 21, 2019
EPS / Forecast
-- / --
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

PCYC Income Statement

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.